CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
OPERATING EXPENSES
General and administrative	$ 157	$ 552	$ 382	$ 1,024
Research and development	220	283	377	633
Total operating expenses	377	835	759	1,657
Interest and other (income) expenses, net	25	(47)	36	9
Loss from continuing operations before taxes	402	788	795	1,666
Income tax benefit	(12)	(36)	(26)	(198)
NET LOSS	390	752	769	1,468
Less: Net Loss attributable to the noncontrolling interest	0	0	0	0
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 390	$ 752	$ 769	$ 1,468
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutic Corp. stockholders (in dollars per share)	$ 0.01	$ 0.02	$ 0.02	$ 0.04
Basic and diluted shares outstanding (in shares)	40,885	40,885	40,885	40,885